0.00746268656716419 0.00746268656716419 0.00746268656716419 0.00746268656716419 0.0522388059701491 0.00746268656716419 -0.0447761194029851 -0.119402985074627
Sign Up Today X
Thanks for submitting the form.
Stockreport

WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)]

Moleculin Biotech, Inc. (MBRX)  More Company Research Source: Canadian Business Journal
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
VANCOUVER, British Columbia, Feb. 05, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “ Company Moleculin FDA AML A drug that receives Fast Track More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met Rolling Review Mariusz Olejniczak, WPD’s CEO A Fast Track Designation is important for the development of Annamycin as it is not only eligible for accelerated approval and priority review, but it also serves as an important validation of the significant unmet need that we are collectively trying to address with our partners at Moleculin. We strongly believe that Annamycin could become an important treatment for a range of tumors and that ongoing AML studie [Read more]
IMPACT SNAPSHOT EVENT TIME: MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
MBRX alerts
from News Quantified
MBRX
NEWS
MBRX
Earnings
MBRX
Analyst Actions
MBRX
SEC Filings
Stockreport

WPD Pharmaceuticals’ Annamycin Drug Received FDA Approval of Fast Track Designation [Canadian Business Journal (Canada)]

Moleculin Biotech, Inc.  (MBRX) 
More Company Research Source: Canadian Business Journal
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors
VANCOUVER, British Columbia, Feb. 05, 2020 (GLOBE NEWSWIRE) — WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the “ Company Moleculin FDA AML A drug that receives Fast Track More frequent meetings with FDA to discuss the drug’s development plan and ensure collection of appropriate data needed to support drug approval More frequent written communication from FDA about such things as the design of the proposed clinical trials and use of biomarkers Eligibility for Accelerated Approval and Priority Review, if relevant criteria are met Rolling Review Mariusz Olejniczak, WPD’s CEO A Fast Track Designation is important for the development of Annamycin as it is not only eligible for accelerated approval and priority review, but it also serves as an important validation of the significant unmet need that we are collectively trying to address with our partners at Moleculin. We strongly believe that Annamycin could become an important treatment for a range of tumors and that ongoing AML studie [Read more]
IMPACT SNAPSHOT
EVENT TIME:
MBRX
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS